Nicola Fazio

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice
    N Fazio
    Unit of Gastrointestinal and Neuroendocrine Tumor, European Institute of Oncology, Via Ripamonti 435 20141 Milan, Italy
    Curr Med Chem 21:1017-25. 2014
  2. ncbi request reprint Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study
    Nicola Fazio
    European Institute of Oncology, Milan, Italy
    Chest 143:955-62. 2013
  3. doi request reprint Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view
    Nicola Fazio
    Unit of Upper Gastrointestinal and Neuroendocrine Tumors, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Treat Rev 39:270-4. 2013
  4. ncbi request reprint Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma
    N Fazio
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 23:5023-30. 2003
  5. doi request reprint Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
    Nicola Fazio
    European Institute of Oncology, IEO NET Study Group, Via Ripamonti 435, Milan, Italy
    Cancer Treat Rev 36:S87-94. 2010
  6. ncbi request reprint Langerhans' cell histiocytosis
    Nicola Fazio
    European Institute of Oncology, 20141 Milan, Italy
    Lancet 365:598. 2005
  7. ncbi request reprint Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?
    N Fazio
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:13-9. 2007
  8. pmc Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer
    Roberto Biffi
    Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
    World J Gastroenterol 16:868-74. 2010
  9. ncbi request reprint The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrence
    Antonio Chiappa
    Dept of General Surgery, European Institute of Oncology, University of Milano, Italy
    Hepatogastroenterology 54:400-6. 2007
  10. ncbi request reprint Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, Milano, Italy
    Hepatogastroenterology 56:829-34. 2009

Detail Information

Publications48

  1. ncbi request reprint Molecular targeted therapy in enteropancreatic neuroendocrine tumors: from biology to clinical practice
    N Fazio
    Unit of Gastrointestinal and Neuroendocrine Tumor, European Institute of Oncology, Via Ripamonti 435 20141 Milan, Italy
    Curr Med Chem 21:1017-25. 2014
    ..interferon (IFN)-alfa2b, and results are pending. In this review, the biological and clinical aspects of MTAs introduced into clinical practice or which are currently in an advanced phase of clinical investigation are addressed. ..
  2. ncbi request reprint Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study
    Nicola Fazio
    European Institute of Oncology, Milan, Italy
    Chest 143:955-62. 2013
    ..The incidence of neuroendocrine tumors (NETs) has increased approximately fivefold since the 1980s. A similar increase in the incidence of lung NETs has been reported, but therapy has not been optimized...
  3. doi request reprint Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view
    Nicola Fazio
    Unit of Upper Gastrointestinal and Neuroendocrine Tumors, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Treat Rev 39:270-4. 2013
    ..NEC are a category of NET that should be deeply studied to verify if the response to cisplatin/etoposide is homogeneous related to the different Ki67, different morphology and/or different primary site...
  4. ncbi request reprint Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma
    N Fazio
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 23:5023-30. 2003
    ..The aim of this study was to evaluate the activity and safety of giving HIAC through a percutaneous catheter in pre-treated patients...
  5. doi request reprint Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
    Nicola Fazio
    European Institute of Oncology, IEO NET Study Group, Via Ripamonti 435, Milan, Italy
    Cancer Treat Rev 36:S87-94. 2010
    ..Sunitinib data have been presented at the last ASCO in June 2010, and everolimus data will be presented at next ESMO in September 2010...
  6. ncbi request reprint Langerhans' cell histiocytosis
    Nicola Fazio
    European Institute of Oncology, 20141 Milan, Italy
    Lancet 365:598. 2005
  7. ncbi request reprint Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?
    N Fazio
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:13-9. 2007
    ....
  8. pmc Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer
    Roberto Biffi
    Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
    World J Gastroenterol 16:868-74. 2010
    ..To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer...
  9. ncbi request reprint The influence of type of operation for distal rectal cancer: survival, outcomes, and recurrence
    Antonio Chiappa
    Dept of General Surgery, European Institute of Oncology, University of Milano, Italy
    Hepatogastroenterology 54:400-6. 2007
    ..This study analyzed the results of treatment of rectal cancer (tumor within 12 cm of the anal verge) with different techniques...
  10. ncbi request reprint Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, Milano, Italy
    Hepatogastroenterology 56:829-34. 2009
    ....
  11. pmc Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients
    Bruno Andreoni
    Dept of General Surgery, European Institute of Oncology, University of Milano, Italy
    World J Surg Oncol 5:73. 2007
    ..This study evaluates the surgical morbidity and long-term outcome of colorectal cancer surgery in an unselected group of patients treated over the period 1994-2003...
  12. ncbi request reprint Surgery for advanced colorectal cancer in elderly patients with special emphasis for radio-chemotherapy role
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milano, Milano, Italy
    Hepatogastroenterology 54:740-5. 2007
    ..To compare the short- and long-term outcome of older and younger patients with advanced colorectal cancer who underwent elective surgery...
  13. doi request reprint Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer
    Katia Lorizzo
    Department of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Cancer Chemother Pharmacol 64:301-6. 2009
    ..Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates...
  14. doi request reprint No impact of central venous insertion site on oncology patients' quality of life and psychological distress. A randomized three-arm trial
    Roberto Biffi
    Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Support Care Cancer 19:1573-80. 2011
    ..Though totally implantable access ports (TIAP) are extensively used, information from randomized trials about the impact of insertion site on patient's quality of life (QoL) and psychological distress is unavailable...
  15. doi request reprint Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer
    Maria Giulia Zampino
    Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Int J Radiat Oncol Biol Phys 75:421-7. 2009
    ....
  16. pmc Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours
    Francesca Spada
    Upper GI and NET Unit, Department of Medicine, European Institute of Oncology IEO, Via Ripamonti 435, 20141 Milan, Italy
    Ecancermedicalscience 6:280. 2012
    ..Primary liver tumours (PLTs) are currently a major health problem worldwide. The study's aim was to investigate the feasibility, toxicity, and activity of hepatic intra-arterial chemotherapy (HIAC) in patients with advanced PLTs...
  17. doi request reprint Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases
    Francesca Spada
    Department of Medicine, Upper Gastro Intestinal Tract and Neuroendocrine Tumors Unit, and European Institute of Oncology, Milan, Italy
    Tumori 98:53e-56e. 2012
    ..Both patients experienced minimal toxicity, suggesting that SO can be safely administered to elderly patients...
  18. ncbi request reprint The Ligasure vessel sealer in liver resection: a pilot study
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, Milano, Italy
    Hepatogastroenterology 54:2353-7. 2007
    ..This study evaluates alternative energy sources in sealing ductal structures for use in liver resection with minimal blood loss...
  19. doi request reprint Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy
    Daris Ferrari
    Department of Oncology, San Paolo Hospital, Milan, Italy
    Anticancer Drugs 19:837-40. 2008
    ..It is suggested that an aggressive regimen like ECF should be considered in fit patients who are not affected by concomitant liver disease...
  20. doi request reprint High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases
    Gianluigi Orgera
    Unit of Interventional Radiology, European Institute of Oncology, 20141, Milan, Italy
    Cardiovasc Intervent Radiol 34:419-23. 2011
    ..HIFU is likely to be a valid alternative for symptoms control in patients with pancreatic NETs. However, currently the procedure should be reserved for inoperable patients for whom symptoms cannot be controlled by medical therapy...
  21. doi request reprint Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience
    Giuseppe Petralia
    Department of Radiology, European Institute of Oncology, University of Milan, Milan, Italy
    J Comput Assist Tomogr 35:195-201. 2011
    ..The objective of the study was to evaluate the role of perfusion computed tomography (CT) for monitoring and predicting therapy response in patients with hepatocellular carcinoma treated with thalidomide...
  22. doi request reprint Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma
    Gaetano Aurilio
    European Institute of Oncology, Medical Care Unit, Department of Medical Oncology, Milan, Italy
    Tumori 97:239-42. 2011
    ..The available therapies do not improve the poor prognosis and it is difficult to find long-term survivors (more than 1 year), even after demolitive surgery with complementary therapies...
  23. doi request reprint Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial
    R Biffi
    Division of Abdomino Pelvic Surgery, European Institute of Oncology, Via Ripamonti 435, I 20141 Milan, Italy
    Ann Oncol 20:935-40. 2009
    ..Central venous access is extensively used in oncology, though practical information from randomized trials on the most convenient insertion modality and site is unavailable...
  24. ncbi request reprint Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapy
    D Ravizza
    Endoscopy Gastroenterology Division, European Institute of Oncology, Milan, Italy
    Hepatogastroenterology 50:49-53. 2003
    ..The aim of this study was to analyze a homogeneous cohort of patients in order to evaluate the evolution and management of this complication...
  25. doi request reprint Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
    M G Zampino
    Department of Medicine, Medical Care Unit, European Institute of Oncology, Milan, Italy
    Cancer Chemother Pharmacol 63:139-48. 2008
    ..Main biological objective was to assess sEGFR as surrogate marker of tyrosine kinase inhibition and as predictor of response...
  26. ncbi request reprint Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Support Care Cancer 13:194-5. 2005
  27. ncbi request reprint Activity and tolerability of courses of intra-arterial chemotherapy followed by chemoembolization in unresectable hepatocellular carcinoma
    M Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Tumori 84:673-6. 1998
    ..a.) chemotherapy and chemoembolization in unresectable hepatocellular carcinoma. We therefore evaluated a new program combining three courses of i.a. chemotherapy with chemoembolization administered every 28 days...
  28. ncbi request reprint Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours
    D Ravizza
    European Institute of Oncology, Division of Endoscopy, Via Ripamonti 435, Milan, Italy
    Dig Liver Dis 39:537-43. 2007
    ..Based on the favourable behaviour of this neoplasm, we performed an endoscopic and clinical follow-up in 11 patients affected by type 1 gastric neuroendocrine tumours, avoiding any specific treatment...
  29. ncbi request reprint Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
    G Ferretti
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Clin Cancer Res 6:2393-400. 2000
    ..8% test accuracy. The method proposed demonstrated to be specific, accurate, and at relatively low cost but limited by low sensitivity in detecting the presence of neoplastic cells in patients with resectable non-small cell lung cancer...
  30. ncbi request reprint CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours
    G Pelosi
    Divisione di Anatomia Patologica e Medicina di Laboratorio, Istituto Europeo di Oncologia, Milano, Italy
    Virchows Arch 437:270-4. 2000
    ....
  31. ncbi request reprint Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer
    M G Zampino
    Division of Medical Oncology, European Institute of Milan, 20141 Milan, Italy
    Anticancer Res 26:2425-8. 2006
    ..A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported...
  32. doi request reprint Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study
    Lisa Bodei
    Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti, 435 20141 Milan, Italy
    Eur J Nucl Med Mol Imaging 38:2125-35. 2011
    ..The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATE in multiple cycles...
  33. ncbi request reprint Intrathecal chemotherapy in carcinomatous meningitis from breast cancer
    Laura Orlando
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 22:3057-9. 2002
    ..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
  34. ncbi request reprint Chemotherapy in pancreatic adenocarcinoma
    M Squadroni
    Medical Division, European Institute of Oncology, Milan, Italy
    Eur Rev Med Pharmacol Sci 14:386-94. 2010
    ..Therefore, this setting should stimulate studies with new drugs and combinations and potential biological predictive factors...
  35. doi request reprint The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy
    A Chiappa
    Department of General Surgery Laparoscopic Surgery, University of Milano, European Institute of Oncology, Milano, Italy
    Crit Rev Oncol Hematol 72:65-75. 2009
    ....
  36. ncbi request reprint Results of treatment of distal rectal carcinoma since the introduction of total mesorectal excision: a single unit experience, 1994-2003
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, Via G Ripamonti 435, 20141 Milan, Italy
    Int J Colorectal Dis 20:221-30. 2005
    ..This study reviewed the results of surgery for distal rectal cancer (where the tumour was within 6 cm of the anal verge) following the introduction of total mesorectal excision for rectal cancer in one institution...
  37. ncbi request reprint High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:917-9. 1998
    ..Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination...
  38. ncbi request reprint Practical considerations in the treatment of hepatocellular carcinoma
    M Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Drugs 55:367-82. 1998
    ..HCC patients should be evaluated within clinical trials, possibly randomised and with homogeneous prognostic factors, in order that we may find the answer to all these important questions...
  39. ncbi request reprint Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
    Nicola Fazio
    J Natl Cancer Inst 99:1345-6; author reply 1346-7. 2007
  40. ncbi request reprint Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
    Arnaud D Roth
    Department of Oncosurgery, Oncosurgery Unit, Geneva University Hospital, Geneva 14, Switzerland
    J Clin Oncol 25:3217-23. 2007
    ....
  41. ncbi request reprint Docetaxel in advanced gastric cancer--review of the main clinical trials
    Serena Di Cosimo
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Acta Oncol 42:693-700. 2003
    ..The future results of the above phase III studies could indicate docetaxel as a key drug to improve treatment of patients with advanced gastric cancer...
  42. ncbi request reprint Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors
    Nicola Fazio
    J Clin Oncol 22:573-4; author reply 574-5. 2004
  43. ncbi request reprint Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma
    Piercarlo Saletti
    Istituto Oncologico della Svizzera Italiana IOSI, Bellinzona, Switzerland
    Hepatogastroenterology 54:969-72. 2007
    ..ECF is an active regimen in advanced gastric adenocarcinoma (GAC). We used ECF as an adjuvant therapy in a cohort of patients with GAC who underwent curative surgery and describe their results in terms of feasibility and outcome...
  44. ncbi request reprint Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma
    Giovanni Di Meglio
    Acta Oncol 46:1205-6. 2007
  45. ncbi request reprint Surgical treatment of advanced colorectal cancer in the elderly
    Antonio Chiappa
    Department of General Surgery, European Institute of Oncology, University of Milan
    Chir Ital 57:589-96. 2005
    ..0001) correlated significantly with overall survival rates in the elderly. Colorectal surgery for malignancy can be performed safely in the elderly with acceptable morbidity and mortality rates and long-term survival...
  46. ncbi request reprint Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma
    Nicola Fazio
    Acta Oncol 45:627-9. 2006
  47. ncbi request reprint Target-treatment and patients' selection: can we still neglect the timing of tissue collection?
    Tommaso De Pas
    J Clin Oncol 23:6274-5; author reply 6275-6. 2005
  48. ncbi request reprint Temsirolimus for advanced renal-cell carcinoma
    Nicola Fazio
    N Engl J Med 357:1050; author reply 1050-1. 2007